Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use):,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - mitoxantrone hydrochloride 2.3284 mg/ml equivalent to mitoxantrone 2 mg/ml. australian approved name is mitozantrone hydrochloride. - solution for injection - 2 mg/ml - active: mitoxantrone hydrochloride 2.3284 mg/ml equivalent to mitoxantrone 2 mg/ml. australian approved name is mitozantrone hydrochloride. excipient: glacial acetic acid hydrochloric acid nitrogen sodium acetate sodium chloride sodium sulfate water for injection - mitozantrone ebewe is indicated for the treatment of: · metastatic carcinoma of the breast · non-hodgkin's lymphoma · adult acute non-lymphocytic leukaemia (anll) · chronic myelogenous leukaemia in blast crisis

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine;  ;   - powder for injection - 200 mg - active: gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine     excipient: mannitol nitrogen sodium acetate as sodium acetate trihydrate sodium hydroxide - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fludarabine phosphate 25 mg/ml - concentrate for injection - 25 mg/ml - active: fludarabine phosphate 25 mg/ml excipient: dibasic sodium phosphate dihydrate sodium hydroxide water for injection - fludarabine ebewe is indicated for the treatment of b-cell chronic lymphocytic leukaemia.

Malta - English - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - irinotecan - concentrate for solution for infusion - irinotecan 17.33 mg - antineoplastic agents

Malta - English - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - irinotecan - concentrate for solution for infusion - irinotecan 17.33 mg - antineoplastic agents

Malta - English - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - irinotecan - concentrate for solution for infusion - irinotecan 17.33 mg - antineoplastic agents

Malta - English - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - irinotecan - concentrate for solution for infusion - irinotecan 17.33 mg - antineoplastic agents

Malta - English - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - irinotecan - concentrate for solution for infusion - irinotecan 17.33 mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml;   - concentrate for injection - 10 mg/ml - active: gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml   excipient: sodium acetate trihydrate sodium hydroxide water for injection - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.